Literature DB >> 26488852

Targets to treat metabolic syndrome in polycystic ovary syndrome.

Shruthi Mahalingaiah1, Evanthia Diamanti-Kandarakis2.   

Abstract

INTRODUCTION: Metabolic syndrome is comprised of a combination of the following states: increased insulin resistance, dyslipidemia, cardiovascular disease, and increased abdominal obesity. Women with polycystic ovary syndrome (PCOS) have an increased risk of developing metabolic syndrome over the course of their lives. Metabolic syndrome increases risk of major cardiovascular events, morbidity, quality of life, and overall health care costs. Though metabolic syndrome in women with PCOS is an area of great concern, there is no effective individual medical therapeutic to adequately treat this issue. AREAS COVERED: This article will review key aspects of metabolic syndrome in PCOS. We will discuss classic and novel therapeutics to address metabolic syndrome in women with PCOS. We will conclude with the importance of developing strategic interventions to increase the compliance to lifestyle and dietary modification, in addition to appreciation of the emerging pharmaceutical therapeutics available. EXPERT OPINION: Innovation in lifestyle modification, including diet, exercise, with and without dedicated stress reduction techniques is the future in treatment of metabolic syndrome in PCOS. Application of novel interventions, such as group medical care, may improve future adherence to lifestyle modification recommendations, in addition to or in combination with pharmaceutical therapeutics.

Entities:  

Keywords:  group care; lifestyle modification; metabolic syndrome; polycystic ovary syndrome

Mesh:

Year:  2015        PMID: 26488852      PMCID: PMC4883581          DOI: 10.1517/14728222.2015.1101067

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  163 in total

Review 1.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.

Authors:  D Steinberg; S Parthasarathy; T E Carew; J C Khoo; J L Witztum
Journal:  N Engl J Med       Date:  1989-04-06       Impact factor: 91.245

Review 2.  Metformin for the treatment of the polycystic ovary syndrome.

Authors:  John E Nestler
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

3.  Thuja occidentalis L. and its active compound, α-thujone: Promising effects in the treatment of polycystic ovary syndrome without inducing osteoporosis.

Authors:  Esra Küpeli Akkol; Mert İlhan; Mürşide Ayşe Demirel; Hikmet Keleş; Ibrahim Tümen; İpek Süntar
Journal:  J Ethnopharmacol       Date:  2015-03-27       Impact factor: 4.360

4.  Metformin versus acarbose therapy in patients with polycystic ovary syndrome (PCOS): a prospective randomised double-blind study.

Authors:  Aida Hanjalic-Beck; Boris Gabriel; Wolfgang Schaefer; Hans-Peter Zahradnik; Marcus Schories; Clemens Tempfer; Christoph Keck; Dominik Denschlag
Journal:  Gynecol Endocrinol       Date:  2010-09       Impact factor: 2.260

Review 5.  Medical management of metabolic dysfunction in PCOS.

Authors:  Antoni J Duleba
Journal:  Steroids       Date:  2011-12-13       Impact factor: 2.668

6.  Effects of the amount and intensity of exercise on plasma lipoproteins.

Authors:  William E Kraus; Joseph A Houmard; Brian D Duscha; Kenneth J Knetzger; Michelle B Wharton; Jennifer S McCartney; Connie W Bales; Sarah Henes; Gregory P Samsa; James D Otvos; Krishnaji R Kulkarni; Cris A Slentz
Journal:  N Engl J Med       Date:  2002-11-07       Impact factor: 91.245

7.  Effect of lifestyle modification and metformin therapy on emerging cardiovascular risk factors in overweight Indian women with polycystic ovary syndrome.

Authors:  Gadekal Rajagopal; Amaresh P Reddy; Chittari Venkata Harinarayan; Vaikkakara Suresh; Aparna Bitla; Srinivasa P V L N Rao; Alok Sachan
Journal:  Metab Syndr Relat Disord       Date:  2012-04-02       Impact factor: 1.894

Review 8.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

9.  The treatment of polycystic ovary syndrome.

Authors:  S Ajossa; S Guerriero; A M Paoletti; M Orrù; G B Melis
Journal:  Minerva Ginecol       Date:  2004-02

Review 10.  Not all women diagnosed with PCOS share the same cardiovascular risk profiles.

Authors:  Vuk P Jovanovic; Enrico Carmina; Rogerio A Lobo
Journal:  Fertil Steril       Date:  2009-06-06       Impact factor: 7.329

View more
  9 in total

Review 1.  Cardiometabolic Features of Polycystic Ovary Syndrome: Role of Androgens.

Authors:  Licy L Yanes Cardozo; Damian G Romero; Jane F Reckelhoff
Journal:  Physiology (Bethesda)       Date:  2017-09

2.  The effectiveness of metformin, oral contraceptives, and lifestyle modification in improving the metabolism of overweight women with polycystic ovary syndrome: a network meta-analysis.

Authors:  Anran Wang; Tingting Mo; Qiao Li; Chuangpeng Shen; Min Liu
Journal:  Endocrine       Date:  2019-03-25       Impact factor: 3.633

Review 3.  The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: a meta-analysis.

Authors:  J J Ge; D J Wang; W Song; S M Shen; W H Ge
Journal:  J Endocrinol Invest       Date:  2021-08-29       Impact factor: 4.256

4.  A Practitioner's Toolkit for Polycystic Ovary Syndrome Counselling.

Authors:  Tejal Lathia; Ameya Joshi; Arti Behl; Atul Dhingra; Bharti Kalra; Charu Dua; Kiran Bajaj; Komal Verma; Neharika Malhotra; Preeti Galagali; Rakesh Sahay; Samta Mittal; Sarita Bajaj; Smitha Moorthy; Suresh Sharma; Sanjay Kalra
Journal:  Indian J Endocrinol Metab       Date:  2022-04-27

5.  Insulin Sensitizers for Improving the Endocrine and Metabolic Profile in Overweight Women With PCOS.

Authors:  Chuan Xing; Chunzhu Li; Bing He
Journal:  J Clin Endocrinol Metab       Date:  2020-09-01       Impact factor: 5.958

Review 6.  Polycystic ovary syndrome and mitochondrial dysfunction.

Authors:  Jingshun Zhang; Yigang Bao; Xu Zhou; Lianwen Zheng
Journal:  Reprod Biol Endocrinol       Date:  2019-08-16       Impact factor: 5.211

7.  An Untargeted Lipidomics Study of Acute Ischemic Stroke with Hyperglycemia Based on Ultrahigh-Performance Liquid Chromatography-Mass Spectrometry.

Authors:  Jia Guo; Hailan Wang; Xin Jiang; Yan Wang; Zhihao Zhang; Qingbin Liao; Jia Xu
Journal:  Comput Math Methods Med       Date:  2022-08-26       Impact factor: 2.809

8.  Insulin Resistance in PCOS Patients Enhances Oxidative Stress and Leukocyte Adhesion: Role of Myeloperoxidase.

Authors:  Victor M Victor; Susana Rovira-Llopis; Celia Bañuls; Noelia Diaz-Morales; Arantxa Martinez de Marañon; Cesar Rios-Navarro; Angeles Alvarez; Marcelino Gomez; Milagros Rocha; Antonio Hernández-Mijares
Journal:  PLoS One       Date:  2016-03-23       Impact factor: 3.240

9.  Long-Lasting Androgen-Induced Cardiometabolic Effects in Polycystic Ovary Syndrome.

Authors:  Edgar D Torres Fernandez; Kristen V Adams; Maryam Syed; Rodrigo O Maranon; Damian G Romero; Licy L Yanes Cardozo
Journal:  J Endocr Soc       Date:  2018-07-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.